{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:07:32Z","timestamp":1762160852099},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/nrclinonc.2010.151","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T11:36:22Z","timestamp":1285760182000},"page":"557-558","source":"Crossref","is-referenced-by-count":4,"title":["Nilotinib and dasatinib\u2014new 'magic bullets' for CML?"],"prefix":"10.1038","volume":"7","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,29]]},"reference":[{"key":"BFnrclinonc2010151_CR1","doi-asserted-by":"crossref","first-page":"a1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger, M. et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood 114, a1126 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2010151_CR2","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin, D. et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112, 4437\u20134444 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2010151_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes, J. E. et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28, 424\u2013430 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2010151_CR4","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah, N. P. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant chronic phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204\u20133212 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2010151_CR5","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian, H. M. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540\u20133546 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2010151_CR6","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti, G. et al Nilotinib for the frontline treatment of Ph+ chronic myeloid leukaemia. Blood 114, 4933\u20134938 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2010151_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes, J. E. et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukaemia. J. Clin. Oncol. 28, 398\u2013404 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2010151_CR8","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio, G. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N. Engl. J. Med. 362, 2251\u20132259 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2010151_CR9","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian, H. M. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia. N. Engl. J. Med. 362, 2260\u20132270 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2010151_CR10","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani, M. et al. Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041\u20136051 (2009).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.151","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:04:42Z","timestamp":1684469082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,29]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BFnrclinonc2010151"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2010.151","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,29]]}}}